X. Guan

发表

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

D. Klonoff, J. Buse, D. Maggs, 2008, Current medical research and opinion.

The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

C. Schnabel, M. Fineman, X. Guan, 2007, Diabetes technology & therapeutics.

Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.

Tae Won Kim, P. Ruff, M. Peeters, 2016, European journal of cancer.

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

R. DeFronzo, L. Macconell, X. Guan, 2008, Current medical research and opinion.

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma

M. Peeters, A. Zaniboni, M. Valladares-Ayerbes, 2018, ESMO Open.

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

J. Hecht, G. Fasola, J. Canon, 2017, International Journal of Colorectal Disease.

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

R. DeFronzo, L. Macconell, X. Guan, 2008, Current medical research and opinion.

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis

J. Douillard, M. Valladares-Ayerbes, F. Rivera, 2016 .

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

A. Bardelli, E. Van Cutsem, J. Tabernero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

A. Bardelli, J. Tabernero, M. Boedigheimer, 2015 .

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Joon-Oh Park, Tae Won Kim, C. Lofton-Day, 2016, British Journal of Cancer.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years*

D. Klonoff, J. Buse, D. Maggs, 2008 .

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

D. Klonoff, J. Buse, D. Maggs, 2007, Clinical therapeutics.

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.

M. Fineman, J. Malloy, P. Kothare, 2009, Clinical therapeutics.

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer

Joon-Oh Park, Tae Won Kim, C. Lofton-Day, 2018, Clinical colorectal cancer.

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

N. Raje, E. Terpos, X. Guan, 2018, Blood.

Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.

Tae Won Kim, P. Ruff, M. Peeters, 2016, European Journal of Cancer.